23
Apr
2026

Lilly Buys In Vivo CAR-T, Psychedelics in the Fast Lane, Nektar Surges on Hair Loss Drug

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

UCB Takes Over Candid, Odyssey’s IPO & Makary’s Rough Week
An IPO Trio, Veradermics’ Hair Loss Win, & Erasca’s Rough Week
RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds